June 2021
Volume 62, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2021
Suppression of Murine Choroidal and Retinal Neovascularization by Risuteganib and the Accompanying Transcriptome Changes in the OIR Retina
Author Affiliations & Notes
  • Zixuan Shao
    Allegro Ophthalmics, LLC, California, United States
  • Sean F. Hackett
    Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
  • Raquel Formica
    Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
  • Yogita Kanan
    Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
  • Dan Zhou
    California Institute of Technology Division of Chemistry and Chemical Engineering, Pasadena, California, United States
  • John Y Park
    Allegro Ophthalmics, LLC, California, United States
  • Hampar L Karageozian
    Allegro Ophthalmics, LLC, California, United States
  • Vicken H Karageozian
    Allegro Ophthalmics, LLC, California, United States
  • Peter A Campochiaro
    Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
  • Julia A. Kornfield
    California Institute of Technology Division of Chemistry and Chemical Engineering, Pasadena, California, United States
  • Footnotes
    Commercial Relationships   Zixuan Shao, Allegro Ophthalmics (E); Sean Hackett, None; Raquel Formica, None; Yogita Kanan, None; Dan Zhou, None; John Park, Allegro Ophthalmics (E); Hampar Karageozian, Allegro Ophthalmics (E); Vicken Karageozian, Allegro Ophthalmics (E); Peter Campochiaro, Allegro Ophthalmics (C); Julia Kornfield, Allegro Ophthalmics (C)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2021, Vol.62, 186. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Zixuan Shao, Sean F. Hackett, Raquel Formica, Yogita Kanan, Dan Zhou, John Y Park, Hampar L Karageozian, Vicken H Karageozian, Peter A Campochiaro, Julia A. Kornfield; Suppression of Murine Choroidal and Retinal Neovascularization by Risuteganib and the Accompanying Transcriptome Changes in the OIR Retina. Invest. Ophthalmol. Vis. Sci. 2021;62(8):186.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Wet age-related macular degeneration and diabetic retinopathy are leading causes of blindness with characteristic neovascularization (NV) of the choroid (CNV) or retina (RNV), respectively. This preclinical study explores effects of the investigational drug, risuteganib (RSG), in cell culture and three murine disease models using histology and transcriptomics.

Methods : In photocoagulation-induced CNV model, 1-50µg RSG or control peptides were intraocularly injected, followed by measurement of NV area on day 14 (n=4). The rho/VEGF model of subretinal NV was used to examine: i) injection of vehicle, 25µg RSG, 10μg ranibizumab, or combination of two drugs, followed by NV area measurement on day 7 (n=5), and ii) vascular leakage 1 day after PBS or 25µg RSG injection (n=8). In oxygen-induced retinopathy (OIR) RNV model, 0.1-50µg of RSG or PBS were injected and NV area was measured on day 5 (n=8). Student’s t-test was used except with ANOVA in the rho/VEGF study of NV. Transcriptome changes associated with RNV and 10µg RSG injection was measured by RNA-seq. Changes in gene levels were determined by edgeR and enrichment of biological processes/pathways by goseq. RT-CES-based HREC cell adhesion and migration assays were used to test effect of 43-1393µM RSG on surfaces coated with vitronectin (VN) or fibronectin (FN) (n=2), statistical test by ANOVA.

Results : In the photocoagulation model, 10 and 25µg RSG reduced the area of CNV (p=0.0453, 0.0498). In the rho/VEGF model, RSG (p<0.001) and ranibizumab (p<0.001) both reduced NV area, while combination showed further reduction (p<0.05); RSG reduced vascular leakage by 24% (p=0.017). In OIR, 12.5, 25, and 50µg RSG (p=0.0271, 0.0414, 0.0403) reduced NV area. Transcriptome data showed biological processes and pathways related to angiogenesis, inflammation, integrin, cell adhesion and migration were enriched in genes elevated in OIR retina and reduced with RSG. Cell migration on FN was inhibited at low RSG dose (p<0.01), while migration on VN (p<0.01), adhesion on VN (p<0.05) and FN (p<0.01) were inhibited at high RSG dose.

Conclusions : RSG demonstrated anti-NV property, reduced retinal vascular leakage, and inhibited cell adhesion and migration. Transcriptome data suggest important pathological cellular responses are modulated by RSG, with possible therapeutic implication for treatment of human retinal diseases.

This is a 2021 ARVO Annual Meeting abstract.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×